RT Journal Article
SR Electronic
T1 1112 A national retrospective study on efficacy of exclusive (chemo)radiotherapy for vulvar cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A361
OP A362
DO 10.1136/ijgc-2021-ESGO.636
VO 31
IS Suppl 3
A1 C Casà
A1 L Tagliaferri
A1 M Ferioli
A1 V Lancellotta
A1 M Boccardi
A1 A Cerrotta
A1 F Tortoreto
A1 E Ippolito
A1 C Laliscia
A1 A Huscher
A1 S Gribaudo
A1 A Giuseppe
A1 R Lazzari
A1 G Garganese
A1 G Macchia
YR 2021
UL http://ijgc.bmj.com/content/31/Suppl_3/A361.abstract
AB Introduction/Background*Vulvar cancer (VC) is a rare gynaecologic cancer with poor outcomes in locally advanced disease. This study aims to evaluate in a retrospective, multicentred, real-world dataset of patients affected by VC efficacy and safety of exclusive (chemo)radiotherapy (eRT), focusing especially to the treatment prescription among participant centers joining the Observational itaLian stuDy on vuLvar cAncer radical raDiotherapY (OLDLADY) project endorsed by the GYN study group of the AIRO (Italian Association of Radiotherapy and Clinical Oncology).Methodology Patients affected by VC and treated by eRT from January 2010 to December 2018 in Seven Italian radiotherapy centers were retrospectively included and clinical data were collected, analysing tumour staging, treatment prescription, clinical and toxicity outcomes.Result(s)*The multicentred retrospective cohort was composed by 90 patients (patient populations shown in table 1), with a median age of 76 years (range 32-92). A considerable heterogeneity was found in the treatment prescription, radiotherapy doses and concomitant chemotherapy schedules. The most relevant acute toxicity revealed for the patient cohort was skin toxicity (26%); instead, the rate of severe skin fibrosis was 4.4%. After a median follow-up of 10 months (range 1-199), the 2-year actuarial local control rate (LC), the 2-year disease free survival rate (DFS) and the overall survival rate (OS) were 42.2%, 40%, and 36.7%, respectively. Kaplan-Meier curves were computed and reported in figure 1.Abstract 1112 Figure 1 Kaplan Meier curves for LC, DFS and OSView this table:Abstract 1112 Table 1 Study populationConclusion*A diverse spectrum of radiotherapy options to exclusively treat patients affected by VC was reported. Clinical outcomes are still confirmed to be poor. The results suggest the clinical evaluation of the impact of treatment standardisation, in terms of doses and volumes, in a further perspective study.